Low-affinity NMDA receptor antagonists. The neuroprotective potential of ARL 15896AR

Annals of the New York Academy of Sciences

Volumn 825, Issue , 1997, Pages 220-231

  Palmer, Gene C ^a   Miller, Jerry A ^a   Cregan, Edward F ^a   Gendron, Patricia ^a   Peeling, James ^b  

^a Astra Arcus USA   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA PHENYL 3 PYRIDINE ETHANAMINE DIHYDROCHLORIDE; GLUTAMATE RECEPTOR; ION CHANNEL; LANICEMINE; MALONIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTEIN KINASE C; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BRAIN HEMORRHAGE; BRAIN HYPOXIA; BRAIN ISCHEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; EPILEPSY; HEAD INJURY; HUMAN; HUNTINGTON CHOREA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MOTOR ACTIVITY; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; SEIZURE; STROKE;

EID: 0030828561     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb48432.x     Document Type: Conference Paper

References (24)

1. HARRIS, E. W. 1995. Subtypes of glutamate receptors: pharmacological classification. In CNS Transmitters and Modulators Glutamate. T. W. Stone, Ed. 95-125. CRC Press. New York.
2. ROGAWSKI, M. A. 1992. The NMDA receptor, NMDA antagonists and epilepsy. Drugs 44: 279-292.
3. PALMER, G. C. & J. B. HUTCHISON. 1996. Preclinical and clinical aspects of remacemide hydrochloride. In Excitatory Amino Acids and Synaptic Transmission - Clinical Aspects. P. Herling, Ed. Chap. 10, pp. 100-120. Academic Press. New York.
4. KIEBURTZ, K., A. FEIGIN, M. MCDERMOTT, P. COMO, D. ABWENDER, C. ZIMMERMAN, C. HICKEY, C. ORME, K. CLAUDE, J. SOTACK, J. T. GREENAMYRE, C. DUNN & I. SHOULSON. 1996. A controlled trial of remacemide hydrochloride in Huntington's disease. Movement Disorders 11: 273-277.
5. SHOHAMI, E., M. NOVIKOV & R. MECHOULAM. 1993. A nonpsychotic cannabinoid HU-211 has cerebroprotective effects after closed head injury in the rat. J. Head Trauma 10: 109-119.
6. PALMER, G. C., R. J. MURRAY & D. J. MCCARTHY. 1996. Neuroprotective potential of the low affinity NMDA receptor antagonist, ARL 15896AR. In 4th Annual Symposium on Advances in the Understanding and Therapy of Ischemic Stroke. L. M. Savage, Ed. Chap. 1.2, pp. 34-64. Internat. Bus. Commun. Southborough, MA.
7. HUDZIK, T. J. & G. C. PALMER. 1995. Effects of anticonvulsants in a novel operant learning paradigm in rats: comparison of remacemide hydrochloride and FPL 15896AR to other anticonvulsant agents. Epilepsy Res. 21: 183-193.
8. HUDZIK, T. J., L. FREEDMAN & G. C. PALMER. 1996. Remacemide hydrochloride and ARL 15896AR lack abuse potential: additional differences from other uncompetitive NMDA antagonists. Stroke 37: 544-550.
9. BLACK, M. A., R. TREMBLAY, G. MEALING, R. RAY, J. P. DURKIN, J. F. WHITFIELD, J. F. BLOSSER & P. MORLEY. 1995. N-methyl-D-aspartate- or glutamate-mediated toxicity in cultured rat cortical neurons is antagonized by FPL 15896AR. J. Neurochem. 65: 2170-2177.
10. CREGAN, E. F., A. S. HOWELL, M. L. STAGNITTO, R. J. MURRAY, J. A. MILLER & G. C. PALMER. 1995. Protection of rodents against global ischemia by FPL 15896AR. Soc. Neurosci. 21: 995.
11. BLACK, M. A., T. LANTHORN, D. L. SMALL, G. A. R. MEALING, V. LAM & P. MORLEY. 1996. Study of potency, kinetics of block and toxicity of NMDA antagonists using fura-2. Eur. J. Pharmacol. 317: 377-381.
12. MEALING, G. A. R., T. H. LANTHORN, D. L. SMALL, M. A. BLACK, N. B. LAFERRIERE & P. MORLEY. Antagonism of NMDA-evoked currents in rat cortical cultures by ARL 15896AR. J. Pharmacol. Exp. Ther. In press.
13. PORTER, H. P. & J. T. GREENAMYRE. 1995. Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochem. 64: 614-623.
14. GREENE, J. G., R. H. PORTER & J. T. GREENAMYRE. 1996. ARL-15896, a novel N-methyl-D-aspartate receptor ion channel antagonist: neuroprotection against mitochondrial metabolic toxicity and regional pharmacology. Exp. Neurol. 137: 66-72.
15. KNOWLES, M. A., C. L. CRAMER, M. L. STAGNITTO, L. R. FREEDMAN, B. E. WATKINS, R. J. MURRAY, M. BALESTRA & G. C. PALMER. 1995. Anti-epileptic potential of FPL 15896AR. FASEB J. 9: A394.
16. MACDONALD, R. L. 1989. Antiepileptic drug action. Epilepsia 30 (Suppl. 1): S19-S28.
17. SU, T-P. 1993. Delineating biochemical and functional properties of sigma receptors: emerging concepts. Crit. Rev. Neurobiol. 7: 187-203.
18. OLNEY, J. W. 1978. Neurotoxicity of excitatory amino acids. In Kainic Acid as a Tool in Neurobiology. E. G. McGeer, J. W. Olney & P. L. McGeer, Eds. 95-121. Raven Press. New York.
19. CREGAN, E. F., J. PEELING, D. CORBETT, A. M. BUCHAN, J. SAUNDERS, R. N. AUER, M. GAO, D. J. MCCARTHY, M. S. EISMAN, T. M. CAMPBELL, R. J. MURRAY, M. L. STAGNITTO & G. C. PALMER. ARL 15896AR a low affinity uncompetitive NMDA antagonist is effective in rodent models of global and focal ischemia. J. Pharmacol. Exp. Ther. Submitted.
20. PALMER, G. C., E. F. CREGAN, A. R. BORRELLI, E. W. HARRIS, M. L. STAGNITTO, P. COLOMBO, F. C. KAISER, R. J. MURRAY, R. C. GRIFFITH & J. C. STRAND. 1995. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia. J. Pharmacol. Exp. Ther. 274: 991-1000.
21. BUCHAN, A. M., D. XUE & A. SLIVKA. 1992. A new model of temporary focal neocortical ischemia in the rat. Stroke 23: 273-279.
22. LONGA, E. Z., P. R. WEINSTEIN, S. CARLSON & R. CUMMINGS. 1989. Reversible middle cerebral artery occlusion without craniotomy in rats. Stroke 20: 84-91.
23. SUTHERLAND, G. R., F-Y. YANG, D. MCCARTHY & J. K. SAUNDERS. 1997. Effect of ARL 15896AR on focal cerebral ischemia in cat. 22nd Annu. Joint Conf. Stroke Cerebral Ischemia, Anaheim, CA.
24. DEL BIGIO, M. R., H-J. YAN, R. BUIST & J. PEELING. Experimental intracerebral hemorrhage in rat: magnetic resonance imaging and histopathological correlates. Stroke. In press.